Suppr超能文献

疫苗佐剂:原因与方式。

Vaccine adjuvants: Why and how.

作者信息

Christensen Dennis

机构信息

a Vaccine Adjuvant Research, Department of Infectious Disease Immunology, Statens Serum Institut , Copenhagen , Denmark.

出版信息

Hum Vaccin Immunother. 2016 Oct 2;12(10):2709-2711. doi: 10.1080/21645515.2016.1219003.

Abstract

Novel vaccine strategies include the so-called subunit vaccines, which encompass only the part of the pathogen to which immune recognition results in protection. The high purity of these vaccines make adverse events less likely, but it also makes the vaccines less immunogenic and therefore potentially less effective. Vaccine adjuvants that increase and modulate the immunogenicity of the vaccine are therefore added to solve this problem. Besides aluminum salts, which have been used in vaccines for 90 years, a number of novel vaccine adjuvants have been included in licensed vaccines over the last 30 years. Increasing insight into immunological mechanisms and how to manipulate them has replaced empirical with rational design of adjuvants, leading to vaccine adjuvants with increased and customized immunogenicity profiles without compromising vaccine safety.

摘要

新型疫苗策略包括所谓的亚单位疫苗,这类疫苗仅包含病原体中能引发免疫识别并产生保护作用的部分。这些疫苗的高纯度降低了不良事件发生的可能性,但同时也降低了疫苗的免疫原性,因此可能效果欠佳。为解决这一问题,会添加增强和调节疫苗免疫原性的疫苗佐剂。除了已在疫苗中使用90年的铝盐外,在过去30年里,一些新型疫苗佐剂已被纳入获批疫苗中。对免疫机制以及如何操控这些机制的深入了解,已使佐剂设计从经验式走向了理性化,从而带来了免疫原性增强且特性定制化、同时又不影响疫苗安全性的疫苗佐剂。

相似文献

1
Vaccine adjuvants: Why and how.
Hum Vaccin Immunother. 2016 Oct 2;12(10):2709-2711. doi: 10.1080/21645515.2016.1219003.
2
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Int J Pharm. 2008 Dec 8;364(2):272-80. doi: 10.1016/j.ijpharm.2008.04.036. Epub 2008 Apr 30.
3
Unmet needs in modern vaccinology: adjuvants to improve the immune response.
Vaccine. 2010 Aug 31;28 Suppl 3:C25-36. doi: 10.1016/j.vaccine.2010.07.021.
4
Vaccine adjuvants: smart components to boost the immune system.
Arch Pharm Res. 2017 Nov;40(11):1238-1248. doi: 10.1007/s12272-017-0969-z. Epub 2017 Oct 13.
5
What are the limits of adjuvanticity?
Vaccine. 2001 Oct 15;20 Suppl 1:S38-41. doi: 10.1016/s0264-410x(01)00288-2.
6
Design and selection of vaccine adjuvants: animal models and human trials.
Vaccine. 2002 May 31;20 Suppl 3:S56-64. doi: 10.1016/s0264-410x(02)00174-3.
7
An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.
Expert Rev Vaccines. 2017 May;16(5):491-502. doi: 10.1080/14760584.2017.1306440. Epub 2017 Mar 20.
8
The development and use of vaccine adjuvants.
Mol Biotechnol. 2002 Jun;21(2):129-48. doi: 10.1385/MB:21:2:129.
9
Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.
Drug Discov Today. 2003 Oct 15;8(20):934-43. doi: 10.1016/s1359-6446(03)02864-2.
10
Vaccine adjuvants.
Semin Vet Med Surg Small Anim. 1997 Aug;12(3):206-11. doi: 10.1016/s1096-2867(97)80034-5.

引用本文的文献

1
Applications of Chitosan in Prevention and Treatment Strategies of Infectious Diseases.
Pharmaceutics. 2024 Sep 13;16(9):1201. doi: 10.3390/pharmaceutics16091201.
2
Ontological representation, modeling, and analysis of parasite vaccines.
J Biomed Semantics. 2024 Apr 25;15(1):4. doi: 10.1186/s13326-024-00307-0.
4
Evaluation of three formulations based on Polymorphic membrane protein D in mice infected with .
Front Immunol. 2023 Nov 16;14:1267684. doi: 10.3389/fimmu.2023.1267684. eCollection 2023.
5
6
Effect of Antigen Structure in Subunit Vaccine Nanoparticles on Humoral Immune Responses.
ACS Biomater Sci Eng. 2023 Mar 13;9(3):1296-1306. doi: 10.1021/acsbiomaterials.2c01516. Epub 2023 Feb 27.
7
Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.
J Taibah Univ Med Sci. 2023 Jun;18(3):600-638. doi: 10.1016/j.jtumed.2022.11.007. Epub 2022 Dec 17.
8
Insights into COVID-19 vaccines development: Translation from benchside to bedside.
Health Sci Rev (Oxf). 2022 Sep;4:100040. doi: 10.1016/j.hsr.2022.100040. Epub 2022 Jul 10.
9
The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines.
Health Policy Technol. 2022 Jun;11(2):100619. doi: 10.1016/j.hlpt.2022.100619. Epub 2022 Mar 21.

本文引用的文献

1
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
Vaccine. 2015 Jul 31;33(32):4025-34. doi: 10.1016/j.vaccine.2015.05.088. Epub 2015 Jun 10.
3
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
Vaccine. 2014 Dec 12;32(52):7098-107. doi: 10.1016/j.vaccine.2014.10.036. Epub 2014 Oct 30.
4
The history of MF59(®) adjuvant: a phoenix that arose from the ashes.
Expert Rev Vaccines. 2013 Jan;12(1):13-30. doi: 10.1586/erv.12.140.
5
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
Expert Rev Vaccines. 2010 Dec;9(12):1385-98. doi: 10.1586/erv.10.141.
7
8
New technology platforms in the development of vaccines for the future.
Vaccine. 2002 Dec 20;20 Suppl 5:B10-6. doi: 10.1016/s0264-410x(02)00513-3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验